$4.21
2.18% yesterday
Nasdaq, Dec 23, 10:00 pm CET
ISIN
NL0015436031
Symbol
CVAC

CureVac N.V. Stock price

$4.21
-0.90 17.61% 1M
-1.19 21.96% 6M
+0.80 23.46% YTD
+1.25 42.23% 1Y
-2.08 33.07% 3Y
-96.93 95.84% 5Y
-51.69 92.47% 10Y
-51.69 92.47% 20Y
Nasdaq, Closing price Tue, Dec 23 2025
+0.09 2.18%
ISIN
NL0015436031
Symbol
CVAC
Industry

New AI Insights on CureVac N.V. Insights AI Insights on CureVac N.V.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$927.8m
Enterprise Value
$476.0m
Net debt
positive
Cash
$494.5m
Shares outstanding
225.2m
Valuation (TTM | estimate)
P/E
6.1 | negative
P/S
11.2 | 13.0
EV/Sales
5.7 | 6.7
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
86.8%
Return on Equity
23.3%
ROCE
16.6%
ROIC
25.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$83.4m | $71.4m
EBITDA
$197.7m | $-133.4m
EBIT
$176.9m | $-162.3m
Net Income
$151.9m | $-136.4m
Free Cash Flow
$-147.6m
Growth (TTM | estimate)
Revenue
-87.0% | -88.7%
EBITDA
10.4% | -157.6%
EBIT
13.4% | -177.7%
Net Income
19.0% | -171.5%
Free Cash Flow
-232.3%
Margin (TTM | estimate)
Gross
93.0%
EBITDA
237.0% | -186.8%
EBIT
212.0%
Net
182.1% | -191.0%
Free Cash Flow
-176.8%
More
EPS
$0.7
FCF per Share
$-0.7
Short interest
1.5%
Employees
904
Rev per Employee
$700.0k
Show more

Is CureVac N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

CureVac N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a CureVac N.V. forecast:

6x Buy
50%
6x Hold
50%

Analyst Opinions

12 Analysts have issued a CureVac N.V. forecast:

Buy
50%
Hold
50%

Financial data from CureVac N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
83 83
87% 87%
100%
- Direct Costs 5.83 5.83
97% 97%
7%
78 78
83% 83%
93%
- Selling and Administrative Expenses 98 98
15% 15%
117%
- Research and Development Expense 173 173
12% 12%
207%
198 198
10% 10%
237%
- Depreciation and Amortization 21 21
10% 10%
25%
EBIT (Operating Income) EBIT 177 177
13% 13%
212%
Net Profit 152 152
19% 19%
182%

In millions USD.

Don't miss a Thing! We will send you all news about CureVac N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CureVac N.V. Stock News

Neutral
GlobeNewsWire
21 days ago
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expiration of the initial offering period The subsequent offering period has commenced and will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025   MAINZ, Germany, December 3, 2025 – BioNTec...
Neutral
Seeking Alpha
26 days ago
CureVac N.V. ( CVAC ) Shareholder/Analyst Call November 25, 2025 8:00 AM EST Company Participants Mehdi Shahidi Marco Rau Thaminda Ramanayake - Chief Business Officer & Member of Executive Board Alexander Zehnder - CEO, MD & Member of Management Board Presentation Mehdi Shahidi Welcome, everyone, to this Extraordinary General Meeting of Shareholders of CureVac N.V.
Neutral
Accesswire
28 days ago
TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (Nasdaq:CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of its Extraordinary General Meeting (EGM).
More CureVac N.V. News

Company Profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 904
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today